Literature DB >> 6447741

Ia antigen on peripheral blood mononuclear leukocytes in man. II. Functional studies of HLA-DR-positive T cells activated in mixed lymphocyte reactions.

E G Engleman, C J Benike, D J Charron.   

Abstract

Blast transformation of T cells in response to allogeneic lymphocytes is followed by expression of HLA-DR antigen on up to 60% of the T cells. Murine monoclonal antibody to HLA-DR antigen was used to separate alloactivated T cells into those T cells that express high quantities of DR antigen (DR+) and those that express little or no DR antigen (DR-), and each population was tested in a variety of assays. DR+, but not DR-, T cells stimulated fresh allogeneic and autologous T cells to proliferate and supported proliferation by fresh autologous T cells to soluble antigens. Alloactivated T cells were suppressive of fresh mixed lymphocyte reactions (MLR) and suppression by irradiated DR+ T cells was specific for the DR antigens of the initial stimulator cell. Suppression of the MLR by DR+ T cells was not a result of altered kinetics or cell-mediated cytotoxicity. DR+ T cells released soluble factors that suppressed fresh allogeneic responses. These data indicate that alloactivated DR+ T cells may provide antigen-specific feedback inhibition of the MLR.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6447741

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  13 in total

1.  The alpha chain, not the beta chain of HLA-DR antigens participates in activation of T cells in autologous mixed lymphocyte reaction.

Authors:  R Palacios; L Claesson; G Möller; P A Peterson; E Möller
Journal:  Immunogenetics       Date:  1982       Impact factor: 2.846

Review 2.  Human T lymphocyte subsets. Functional heterogeneity and surface recognition structures.

Authors:  P L Romain; S F Schlossman
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

3.  Antigen presentation to human T lymphocytes. I. Different requirements for stimulation by hapten-modified cells vs. cell sonicates.

Authors:  S L Abramson; J M Puck; R R Rich
Journal:  J Exp Med       Date:  1981-10-01       Impact factor: 14.307

4.  Regulation of the human allogeneic proliferative response in vitro.

Authors:  E Carosella; A Bensussan; V Lepage; M Sasportes
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

5.  Regulation of the human allogenic proliferative response in vitro. II. Production of soluble suppressor factors by suppressor T cells and evidence in favor of "acceptor" cells for suppression among unprimed lymphocytes.

Authors:  M Sasportes; E Carosella; A Bensussan; C Mihaesco; J Dausset
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

6.  Increases in circulating T lymphocytes expressing HLA-DR and CD40 ligand in patients with dilated cardiomyopathy.

Authors:  Atsuko Ueno; Kagari Murasaki; Nobuhisa Hagiwara; Hiroshi Kasanuki
Journal:  Heart Vessels       Date:  2007-09-20       Impact factor: 2.037

7.  Alloantigens expressed on activated human T cells different from HLA-A, B, C, and DR antigens.

Authors:  M Gerbase de Lima; E E Wollman; V Lepage; L Degos; J Dausset
Journal:  Immunogenetics       Date:  1981       Impact factor: 2.846

Review 8.  Autologous cellular immune response to primary and metastatic human melanomas and its regulation by DR antigens expressed on tumor cells.

Authors:  G Parmiani; G Fossati; D Taramelli; A Anichini; A Balsari; C Gambacorti-Passerini; G Sciorelli; N Cascinelli
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

9.  An increase in peripheral blood Ia-positive T cells in Sjögren's syndrome correlates with a decrease in the autologous mixed lymphocyte response.

Authors:  B Sauvezie; N Miyasaka; D Charron; C Kielich; J Loeb; T E Daniels; N Talal
Journal:  Clin Exp Immunol       Date:  1982-07       Impact factor: 4.330

10.  Immunoglobulin secretion in the human autologous mixed leukocyte reaction. Definition of a suppressor-amplifier circuit using monoclonal antibodies.

Authors:  P A Gatenby; B L Kotzin; G S Kansas; E G Engleman
Journal:  J Exp Med       Date:  1982-07-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.